Health Technology Assessment
Drawing on our years of experience of market access strategy and evidence generation, we can support your Health Technology Assessment (HTA) needs on the journey to market access success.
“No nonsense, they deliver high quality work, and a pleasure to work with.”
Reimbursement and Market Access Manager,
Top 20 global biopharma company
What We Offer
Our HTA services can support the full reimbursement journey, from early strategic advice and planning to evidence generation, submission preparation, and submission management.
Our experienced team can provide assessments of likelihood of HTA success and evidence needed to achieve it. We help develop strategies to mitigate potential HTA challenges, including the lack of direct comparator data and immature long-term outcomes. We care about market access success as much as you do.
Why Maverex?
Our highly experienced team is well placed to develop robust, high-quality and defensible materials with a clear clinical and economic narrative aligned with the market access strategy.
Enjoy one team, with multiple specialities; multi-team collaboration with the value communications, modelling, systematic review and statistics teams ensures full alignment, knowledge sharing and high scientific standards.
Examples of Our Services
On hand to support with benchmarking, briefing and more
HTA Submissions and AMCP Dossiers
We develop robust evidence-based submissions, with a focus on concise communication of clinical and economic value.
We can provide practical submission support and management throughout the reimbursement process, from pre-submission to post-submission.
We have an abundance of experience in HTA submissions to NICE, SMC, AWMSG, NCPE and EUnetHTA, as well as AMCP dossiers for the US market.
HTA Benchmarking
Our HTA benchmarking service offers analysis of the drivers behind decisions, and assess previous healthcare interventions to provide valuable insights to inform strategies. Our recommendations help maximise the success of your future submissions.
Early Dialogue and Briefing Books
We support our partners with early dialogue pathways, including the development of effective briefing books for EMA and EUnetHTA parallel consultation, EUnetHTA multi HTA early dialogue, and UK HTA early dialogue.
Patient Voice
Patients are becoming more involved in the development of new interventions. Our reviews explore where and how patients make an input into the decision-making process, and the weight their voice has on recommendations.
Our Services
From Real World Evidence and Environmental Impact Analysis, through to Market Access Materials and more. Maverex are perfectly positioned to support global Pharma and MedTech companies achieve success.
Who We Are
A team of experienced professionals, focused on high-quality solutions and a commitment to environmental responsibility.
Much More to Maverex
Experts in demonstrating product value, from clinical development to post-launch commercialisation.
-
Explore our latest peer-reviewed research publications, across nutrition, disease, the environment, market access and much more.
-
We take a personal approach to every project, and enjoy fantastic feedback from our clients as a result. Discover what they have to say about us on the Testimonials page.